Evidence map›Paper›PMID 35620339›Full record

ArticleAdvanced pharmaceutical bulletin2022

Immunomodulatory Potential of Human Mesenchymal Stem Cells and their Exosomes on Multiple Sclerosis.

Hussein Baharlooi, Zahra Salehi, Moein Minbashi Moeini, Nima Rezaei, Maryam Azimi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced pharmaceutical bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Hussein BaharlooiDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.ORCID https://orcid.org/0000-0003-0892-9511
Zahra SalehiDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Moein Minbashi MoeiniDepartment of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Nima RezaeiDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Maryam AzimiImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences (IUMS), Tehran, Iran.ORCID https://orcid.org/0000-0002-6231-6073
Tehran University of Medical Sciences · IRIran University of Medical Sciences · IRUniversal Scientific Education and Research Network · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ExosomeImmunomodulationMesenchymal stem cellRelapsing-remitting MS

Identifiers

PMID35620339
PMCPMC9106959
OpenAlexW3135793055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.